Patents by Inventor Ivan D. Horak

Ivan D. Horak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PD-1 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210284734
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 16, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen
  • Anti-PD-1 antibodies and compositions
    Patent number: 11034765
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: June 15, 2021
    Assignee: Symphogen A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen
  • ANTI-PD-1 ANTIBODIES AND COMPOSITIONS
    Publication number: 20190144542
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Application
    Filed: September 30, 2016
    Publication date: May 16, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen
  • Methods and compositions for increasing longevity and protein yield from a cell culture
    Patent number: 7531327
    Abstract: Disclosed herein are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. By transfecting cells in culture with an apoptosis-inhibiting gene or vector, cells in culture can survive longer, resulting in extension of the state and yield of protein biosynthesis. Expression of the apoptosis-inhibitor within the cells, because it does not kill the cells, allows the cells, or an increased fraction thereof, to be maintained in culture for longer periods. This invention then allows for controlled, enhanced protein production of cell lines for commercial and research uses, particularly the enhanced production of growth factors, interferons, interleukins, hormones, enzymes, and monoclonal antibodies, and the like.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: May 12, 2009
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Zhengxing Qu, Eva Horak, Ivan D. Horak, Chien Hsing Chang, Edmund A. Rossi, Jeng-Dar Yang